Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 667 antisense RNA 1 (ZNF667-AS1)
- Target
- ZNF667-AS1
- Molecular classification
- Long noncoding RNA (lncRNA), Noncoding RNA
01
Overview
Zinc finger protein 667 antisense RNA 1 (ZNF667-AS1) is a long noncoding RNA located on human chromosome 19q13.43. It regulates cell viability, migration, and invasion by modulating the expression of its sense gene ZNF667 and other targets, functioning primarily as a tumor suppressor in several cancer types. ZNF667-AS1 exerts its biological effects in part by interacting with and recruiting the epigenetic modifying enzyme TET1 to demethylate and activate promoters of genes such as ZNF667 and E-cadherin, thereby inhibiting epithelial–mesenchymal transition and reducing tumor invasiveness. ZNF667-AS1 resides predominantly in the nucleus and acts as a transcriptional regulator. Currently, there are no approved drugs targeting ZNF667-AS1, but its expression may have utility as a biomarker in oncology research.
- Other names
- ZNF667-AS1Zinc finger protein 667 antisense RNA 1lncRNA ZNF667-AS1
02
Mechanism of action
Recruitment of TET1 methylcytosine dioxygenase to promoters (demethylation and gene activation) Epigenetic modulation of target genes (e.g., increasing expression of ZNF667 and E-cadherin, suppressing EMT and tumor cell invasion)
03
Biological functions
Regulation of cell proliferation, migration, and invasionTranscriptional regulation (as an antisense RNA)Modulation of epigenetic mark hydrolysis via recruitment of TET1Inhibition of epithelial–mesenchymal transition (EMT)
04
Disease associations
Cancer (roles described in esophageal squamous cell carcinoma, cervical cancer, and colorectal cancer)Tumor suppressor function
05
Safety considerations
no direct therapeutic targeting information; general challenges relate to lncRNA-based therapies: delivery, specificity, off-target effects, and tissue distribution
06
Biomarkers
Expression levels of ZNF667-AS1 may serve as potential biomarkers for cancer prognosis or progression (not currently in clinical use, but described in research settings)
Beyond the preview
Go deeper on Zinc finger protein 667 antisense RNA 1 (ZNF667-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zinc finger protein 667 antisense RNA 1 (ZNF667-AS1).